Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Ingredion
INGR
$6.27B
| $3.46M | ﹤0.01% |
+30,698
| New | +$3.52M |
|
502
GE Vernova
GEV
$264B
| $3.45M | ﹤0.01% |
3,949
-2,967
| -43% | -$2.31M |
|
503
Coca-Cola Europacific Partners
CCEP
$48.3B
| $3.44M | ﹤0.01% |
37,897
-278
| -0.7% | -$26.7K |
|
504
Tango Therapeutics
TNGX
$4.43B
| $3.4M | ﹤0.01% |
162,399
-25,294
| -13% | -$352K |
|
|
NPKI
505
NPK International
NPKI
$1.06B
| $3.38M | ﹤0.01% |
233,017
+1,046
| +0.5% | +$14.5K |
|
506
State Street Technology Select Sector SPDR ETF
XLK
$115B
| $3.35M | ﹤0.01% |
25,201
-8,809
| -26% | -$1.24M |
|
507
Vanguard Total Bond Market
BND
$157B
| $3.3M | ﹤0.01% |
44,877
-11,430
| -20% | -$848K |
|
508
Simmons First National
SFNC
$3.41B
| $3.29M | ﹤0.01% |
169,280
-13
| -0% | -$260 |
|
509
NextEra Energy
NEE
$181B
| $3.28M | ﹤0.01% |
35,270
+12,448
| +55% | +$1.11M |
|
510
Haleon
HLN
$43.5B
| $3.27M | ﹤0.01% |
327,131
+12,135
| +4% | +$126K |
|
511
Ross Stores
ROST
$80.5B
| $3.25M | ﹤0.01% |
15,005
-3,429
| -19% | -$683K |
|
512
Prosperity Bancshares
PB
$8.97B
| $3.23M | ﹤0.01% |
48,036
-1,034
| -2% | -$72.5K |
|
513
General Mills
GIS
$19.1B
| $3.2M | ﹤0.01% |
85,963
+24,265
| +39% | +$1.05M |
|
514
iShares US Medical Devices ETF
IHI
$3.13B
| $3.17M | ﹤0.01% |
59,364
-31,162
| -34% | -$1.83M |
|
515
AnaptysBio
ANAB
$1.58B
| $3.14M | ﹤0.01% |
56,596
+32
| +0.1% | +$1.72K |
|
516
Vanguard Morningstar Mega Cap Growth ETF
MGK
$32.5B
| $3.04M | ﹤0.01% |
41,330
-9,695
| -19% | -$762K |
|
517
PTC Therapeutics
PTCT
$5.68B
| $3.04M | ﹤0.01% |
+44,558
| New | +$3.16M |
|
518
iShares Russell 1000 Value ETF
IWD
$82.2B
| $2.95M | ﹤0.01% |
13,802
-915
| -6% | -$200K |
|
519
Chemed
CHE
$7.07B
| $2.93M | ﹤0.01% |
7,768
-1,988
| -20% | -$851K |
|
520
State Street SPDR S&P Metals & Mining ETF
XME
$3.87B
| $2.92M | ﹤0.01% |
27,047
-8
| -0% | -$935 |
|
521
iShares S&P 500 Growth ETF
IVW
$73.8B
| $2.9M | ﹤0.01% |
25,674
+47
| +0.2% | +$5.65K |
|
522
L3Harris
LHX
$51.6B
| $2.9M | ﹤0.01% |
8,389
+1,318
| +19% | +$461K |
|
523
AptarGroup
ATR
$8.55B
| $2.87M | ﹤0.01% |
22,757
-319
| -1% | -$41.6K |
|
524
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
$6.1B
| $2.85M | ﹤0.01% |
97,758
-7,307
| -7% | -$214K |
|
525
Woodside Energy
WDS
$44.6B
| $2.83M | ﹤0.01% |
118,604
-24,167
| -17% | -$470K |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.